Zymogenetics, Inc.

Rolf E Kuestner

Paul O Sheppard

Cindy A Sprecher

Jane A Gross

Zeren Gao

Joseph Leon Kuijper

Angela K Hammond

Francis J Grant

Steven D Levin

Emma E Moore

Maria M Dasovich

Darrell C Conklin

Stephen R Jaspers

Janine M Bilsborough

Mark W Rixon

Si Lok

William Downey

Michele Buddle

Scott R Presnell

Steven K Burkhead

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.

Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist

The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Murine zcytor17 ligand polynucleotides

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.

Soluble IL-17RCx4 and fusion proteins thereof

Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation

Murine zcytor17 ligand polypeptides

Method of treating inflammation using soluble IL-17RCX4

Antibodies to murine zcytor17 ligand

Murine ZCYTOR17 ligand polypeptides

The present invention relates to polynucleotide and polypeptide molecules for stanniocalcin-2, a novel member of the stanniocalcin family. The polypeptides, and polynucleotides encoding them, modulate electrolyte homeostasis. The present invention also includes antibodies to the stanniocalcin-2 polypeptides.

Stanniocalcin-2

Human calcitonin receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereto may be used in screening systems to identify agonists and antagonists of human calcitonin receptors, thereby providing means for treating and preventing abnormal bone resorption, as well as in methods of diagnosis.

Methods for identifying modulators of human calcitonin mediated

Human calcitonin receptor polypeptides

Human calcitonin receptor polypeptides and methods of use

Recombinant production of human calcitonin receptor polypeptides

Growing community of inventors

Bothell, WA, United States of America

Rolf E Kuestner